このページの翻訳は実験的なもので、現在開発中です。フィードバックを お待ちしております！
ONCOZ 株式概要 製薬会社OncoZenge AB（publish）は、スウェーデンで、がんの放射線療法や化学療法による口腔内の痛みに苦しむ患者の痛みを和らげる治療薬の開発に取り組んでいる。
価格と性能
Summary of all time highs, changes and price drops for OncoZenge Historical stock prices Current Share Price kr3.32 52 Week High kr7.96 52 Week Low kr1.60 Beta 1.3 1 Month Change -10.39% 3 Month Change -10.99% 1 Year Change -44.48% 3 Year Change -67.61% 5 Year Change n/a Change since IPO -78.16%
最新ニュース
Oncozenge AB (Publ) Appoints Paolo Bossi as Member of the Advisory Board Apr 09
OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge Apr 05
OncoZenge AB (publ) Files Patent Application for Strengthened IP Protection for BupiZenge Feb 07 Oncozenge Announces Formation of Advisory Board with Stephen Sonis and Pooja Nandwani Patel Dec 14
Oncozenge AB (Publ) Confirms the New Formulation of Oncozenge's Drug Candidate Bupizenge™? Is Clean Nov 22
New major risk - Financial position Nov 02 最新情報をもっと見る
Oncozenge AB (Publ) Appoints Paolo Bossi as Member of the Advisory Board Apr 09
OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge Apr 05
OncoZenge AB (publ) Files Patent Application for Strengthened IP Protection for BupiZenge Feb 07 Oncozenge Announces Formation of Advisory Board with Stephen Sonis and Pooja Nandwani Patel Dec 14
Oncozenge AB (Publ) Confirms the New Formulation of Oncozenge's Drug Candidate Bupizenge™? Is Clean Nov 22
New major risk - Financial position Nov 02 Oncozenge AB (Publ) Appoints Stian Kildal as New CEO Sep 14
No independent directors Nov 16
Price target decreased to kr2.75 Apr 27
No independent directors Apr 27
OncoZenge AB (publ) Initiates Toxicity Study and Announces Modification to the Clinical Plan Feb 15 株主還元 ONCOZ SE Pharmaceuticals SE 市場 7D -5.1% -3.6% -1.5% 1Y -44.5% 83.0% 13.0%
株主還元を見る 価格変動 Is ONCOZ's price volatile compared to industry and market? ONCOZ volatility ONCOZ Average Weekly Movement 7.7% Pharmaceuticals Industry Average Movement 9.9% Market Average Movement 5.9% 10% most volatile stocks in SE Market 12.7% 10% least volatile stocks in SE Market 3.5%
会社概要 OncoZenge AB (publish)社は、スウェーデンにおいて、癌の放射線療法や化学療法による口腔内の痛みに苦しむ患者の痛みを和らげる治療薬の開発に従事している製薬会社です。口腔内の疼痛治療薬として臨床第2相試験を完了したBupiZengeを提供している。同社は2020年に設立され、スウェーデンのBrommaに本社を置く。
もっと見る OncoZenge AB (publ) 基礎のまとめ OncoZenge の収益と売上を時価総額と比較するとどうか。 ONCOZ 基礎統計学 時価総額 kr38.89m 収益（TTM） -kr14.22m 売上高(TTM ) kr1.00k
収益と収入 最新の決算報告書（TTM）に基づく主な収益性統計 ONCOZ 損益計算書（TTM） 収益 kr1.00k 売上原価 kr0 売上総利益 kr1.00k その他の費用 kr14.22m 収益 -kr14.22m
一株当たり利益（EPS） -1.21 グロス・マージン 100.00% 純利益率 -1,422,100.00% 有利子負債／自己資本比率 0%
ONCOZ の長期的なパフォーマンスは？
過去の実績と比較を見る
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
